Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Methodology

Draft search-strategy template for the synthesis series

Consultation on the search-strategy template used across the synthesis series: the databases searched, the structure of the strategy, the handling of registry records without posted results, and the requirement that a strategy be published in a form that can…

Document identifier
CEI-CP-036
Series
Public comment period
Version
1.0
Published
13 Jan 2025
Last reviewed
13 Jan 2025
Next review
13 Jan 2026
Identifier
10.71829/cei.cp.36
Certainty
Not rated
Cycle
2024 Q4
Window
02 Nov 2024 – 14 Dec 2024
Status
Closed
Submissions
19

§1Consultation and window

§1.1Window

Opened
2 November 2024
Closed
14 December 2024
Duration
42 days
Status
Closed — the disposition is published
Document under consultation
Methodology
Submissions received
19

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the database set sufficient, and is the omission of any source material to the questions the series addresses?
  2. Should registry records without posted results be screened as studies, or recorded separately as unreported studies?
  3. Is the requirement to publish a re-runnable strategy achievable for every database in the set?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The template was ratified with amendments. Registry records without posted results are screened and then reported as a separate category of unreported study rather than merged with excluded records, and the re-run requirement is stated per database with the limitations of each recorded.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.